<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541760</url>
  </required_header>
  <id_info>
    <org_study_id>163</org_study_id>
    <nct_id>NCT02541760</nct_id>
  </id_info>
  <brief_title>Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children</brief_title>
  <official_title>Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hormozgan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hormozgan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Otitis media is one of the most common infections among children and is a complication in
      about 30% of common colds. The most common complication of acute otitis media is otitis media
      with effusion. Some studies have reported the effects of montelukast and mometasone nasal
      spray in treatment of otitis media with effusion. However, current information is inadequate
      in this issue. The aim of this study was to compare the effectiveness of montelukast and
      mometasone nasal spray in treatment of otitis media with effusion in children attending
      Koodakan hospital in Bandar Abbas, Iran.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response</measure>
    <time_frame>1 months</time_frame>
    <description>Defined as complete, partial, or no response based on the physician examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug side effects</measure>
    <time_frame>1 month</time_frame>
    <description>Frequency of Drug side effects as reported by the children or their parents</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Otitis Media With Effiusion</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 ml monteleukast daily for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled mometasone 1 puff in each side of nose for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monteleukast</intervention_name>
    <description>4 ml monteleukast daily for one month</description>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone</intervention_name>
    <description>Inhaled mometasone 1 puff in each side of nose for one month</description>
    <arm_group_label>Mometasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Children who were between 2 to 6 years old

               -  Definite diagnosis of OME with symptoms and examination

        Exclusion Criteria:

          -  • Currently were using corticosteroids or prophylactic monteleukast

               -  Chronic pulmonary or cardiac diseases or immune deficiency

               -  Allergic rhinitis

               -  Hypersensitivity to monteleukast or corticosteroids

               -  Avoidance of parents to fill the written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamidreza Mahboobi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hormozgan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hormozgan University of Medical Sciences</name>
      <address>
        <city>Bandar Abbas</city>
        <state>Hormozgan</state>
        <zip>097145-3388</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hormozgan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Hamidreza Mahboobi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Otitis Media with Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

